RxDoctor Payments Data

Justin Pickens, APRN

Nurse Practitioner · Port Charlotte, FLNPI 1790371995

Payments from drug & device makers

$2,611in general payments, 2019–2025

Across 118 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$378
  • AstraZeneca$303
  • Regeneron Healthcare Solutions, Inc.$242
  • Boehringer Ingelheim$199
  • Harmony Biosciences LLC$178
  • Merck$167
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,611 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$84,882
Medicare patients
500
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter258$236,969
OfevNintedanib Esylate11$141,125
Breo ElliptaFluticasone/Vilanterol58$27,103
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$17,383
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,894
Spiriva RespimatTiotropium Bromide12$8,188
SymbicortBudesonide/Formoterol Fumarate26$7,951
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$7,685
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$7,353
Wixela InhubFluticasone Propion/Salmeterol53$5,513
Albuterol Sulfate HfaAlbuterol Sulfate254$5,432
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$2,645
Roflumilast18$1,086
Ventolin HfaAlbuterol Sulfate18$1,086
Montelukast Sodium81$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$378$272,966336 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$199$156,66635 claims
AstraZenecaBreztri Aerosphere, Symbicort$303$25,33552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →